CliffBio
small molecule

LENALIDOMIDE

LENALIDOMIDE

Loss of exclusivity—loss of exclusivity
CompanyEUGIA PHARMA SPECIALITIES LTD

Drug detail

Brand nameLENALIDOMIDE
Active ingredientLENALIDOMIDE
Strength2.5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2023
Marketing statusRX

More from EUGIA PHARMA SPECIALITIES LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

LENALIDOMIDE patent cliff — loss of exclusivity — | CliffBio